Aristotle University Of Thessaloniki (AUTH)
Αξιοποίηση της κινναμωμικής ομάδας στον σχεδιασμό, σύνθεση και φαρμακοχημική μελέτη νέων παραγώγων με δράση σε πολλαπλούς βιολογικούς στόχους
Abstract
dc:descriptionCinnamic acids are a group of chemical compounds with a wide variety of biological effects, including: anti-inflammatory activity correlated to the inhibition of various enzymes involved in inflammation, antioxidant activity through scavenging of free radicals, antibacterial, anticancer and analgesic activities. Furthermore, cinnamic acids derivatives are components of various plants, while at the same time being precursors of coumarin derivatives. Due to all these reasons, these compounds are of particular synthetic and biological interest both as final and as intermediate products. The treatment of complex diseases, where more than one biological target is implicated (enzymes or protein receptors), stimulates the interest of investigators, as a single drug is not always able to adequately control the disease and a therapeutic approach through combination of drugs with different therapeutic profiles is frequently used. Such multifactorial phenomena are associated with the development of inflammation, blood coagulation and cancer, where various enzymes are involved, such as cycloxygenase (COX), lipoxygenase (LOX), proteolytic enzymes but also carbonic anhydrase and hCA IX. For the treatment of multi-factorial diseases hybrid drugs have been used, that combine two or more pharmacophore groups on the same scaffold with the goal to create a chemical entity more medically effective than its individual components. In this context, recently there has been an increasing interest in the combination of two pharmacophores for the design and synthesis of multifunctional hybrid molecules.Based on previous research efforts where appropriately substituted cinnamic acids presented significant inhibition of soybean lipoxygenase, this PhD thesis focused on the design and synthesis of even more active LOX inhibitors, through docking simulation binding studies (virtual screening using the model of S-LOX-1), along with 2D-QSAR studies, based on literature data of cinnamic derivatives acting on multiple targets. In this context, new pleiotropic agents were designed, combining substituted cinnamic acids with known drug molecules (e.g. paracetamol, propranolol, atenolol, 4-methylumbelliferone, 1-adamantylamine, 1-adamantanol, benzocaine, sulfonamides) or "drug-like" molecules [e.g., 4-, 7-, coumarins, m-acetamidophenol, p- / m- aminophenol, 2-(benzylamino)ethan-1-ol]. These new hybrid derivatives are divided into two classes: a) esters of cinnamic acid and b) amides of cinnamic acid. The selection of the coumarin scaffold as a structural group for the design and synthesis of multifunctional compounds was based on the fact that the coumarin derivatives present similar biological profile to the cinnamic derivatives. The development of coumarins as antioxidant agents, anticancer and LOX inhibitors has attracted much attention recently. Taking into consideration, the fact that the coumarin ring is an internal ester of o-hydroxy cinnamic acid, indicating the chemical affinity between cinnamic and coumarin derivatives, coumarin derivatives have been included in our study. Moreover, recent studies have demonstrated that 6- and 7- or 6,7-disubstituted coumarin derivatives exhibit effective inhibitory activity against cancer-related carbonic anhydrase isoforms IX and XII. Thus, we proceeded to the development of non-sulphonamide carbonic anhydrase inhibitors of 6/7 coumarinyl-oxy acetic acid derivatives with “drug-likeness” groups. In our design we combine the coumarin ring with the acetic acid group (non-steroidal anti-inflammatory derivatives of acetic acid are known in the literature), which is coupled to “drug-likeness” hetero-, aromatic or aleiphatic amines (phenethylamine, benzylamine, aniline, methyl-aminobenzoate, pyridine, morpholine and piperidine groups etc.), with the aim to design possible pleiotropic agents.The synthesis of cinnamic acid is based on the known condensation reaction between the appropriately substituted aldehyde and malonic acid in the presence of bases. Regarding the synthesis of 6,/7- coumarinyloxy acetic acid, known modified synthetic procedure was followed, where commercially available 6- or 7- coumarins reacted with ethyl iodoacetate, leading to coumarinyloxy- acetic acid ester, which were then hydrolysed in alkaline conditions to the corresponding coumarinyl-acetic acids. These compounds were obtained in good yields, and the physicochemical and spectroscopic data are identical to those reported in the relevant literature.The synthesis of novel hybrid compounds was based on the implementation of known and modified procedures and simple techniques, in an attempt to have efficient yields. The structures of the compounds are identified by IR, 1H-NMR, 13C-NMR, LC/MS, ESI and elemental analysis. Lipophilicity is a physicοchemical property playing a crucial role in the absorption, distribution, and excretion of drug-molecules. Lipophilicity values of compounds were calculated theoretically as ClogP (C-QSAR, Bioloom Biobyte programs) and experimentally by reversed chromatography method as RM values.The physicochemical and pharmacokinetic properties of the newly synthesized compounds were calculated by the implementation of C-QSAR and Molinspiration program. All compounds show molecular weight less than 500, with the exception of the hybrid of phenoxycinnamic acid with m-aminophenol (compound 26), which appears to violate two Lipinski rules. Most of the molecules can be easily transported and diffused, while ten compounds violate the Lipiski rule in terms of lipophilicity.Hybrid compounds were studied by in vitro experiments for their behavour to act as potential lipoxygenase inhibitors, as potential inhibitors of trypsin and as potential inhibitors of the carbonic anhydrase I, II, IV, IX. Their antioxidant activities were determined as well. In particular, the compounds were tested in the following experiments: Pharmacochemical tests in vitro: 1. Inhibition of lipid peroxidation using AAPH [2,2’-azobis-2-methyl-propanimidamide]. 2. Soybean lipoxygenase inhibition assay. 3. Inhibition of proteolytic action of trypsin 4.Inhibition of different isoforms of carbonic anhydrase I, II, IV, IX. Biological experiment in vivo: Behavioral tests were carried out for the evaluation of peripheral nerve damage and possible recovery after administration of the hybrid derivative 3 (naphthyl-substituted cinnamate with paracetamol), which presented the most promising in vitro profile among the paracetamol hybrids. From the obtained results, we find that most of the compounds exhibited a significant ability to inhibit lipid peroxidation of linoleic acid induced by AAPH. Moreover, most of the hybrid compounds exhibit greater anti-lipid peroxidation activity than the precursor cinnamic acids.Biological results confirm that most compounds (2, 5, 6, 7, 8, 11, 13, 14, 15, 22, 23, 24, 27, 28-33) showed pleiotropic activity inhibiting both soybean lipoxygenase and trypsin. In particular, the naphthyl-substituted cinnamic acid hybrid with paracetamol (compound 3) is a dual inhibitor of LOX and trypsin enzymes.The hybrid of phenoxycinnamic acid with 3-acetamidophenol (compound 10) showed significant potent inhibitory activity against LOX (IC50 = 0.34 μM) followed by the amide of the same acid with propranolol (compound 32) presenting IC50 = 6 μM, compared to the reference NDGA compound. The compound 32 combines potent activity also against two biological targets: lipoxygenase and trypsin. The 3,4-dimethoxycinnamic ester of hymechromone (compound 15) highly inhibits trypsin (IC50 = 0.1 μM) followed by the hybrids of atenolol, which appeared to be more active than those of propranolol. Among the tested hybrids of paracetamol most potent were found to be compounds 3, 5 and 8. Significant activity demonstrated by the bromobenzyloxycinnamic acid derivative with hymechromone (compound 14: IC50 = 5 μM). 6/7-coumarinyloxy-acetic acid derivatives did not significantly inhibit the widespread cytosolic isoforms hCA I and II, being weak hCA IV inhibitors, thus making them selective inhibitors of hCA IX. In particular, compound 39 (6-substituted coumarinynyloxyacetamide bearing the benzylamine group) presented significant inhibition of carbonic anhydrase IX, compared to the reference compound, acetazolamide. Compounds 36, 37 are dual inhibitors of LOX and carbonic anhydrase IX. The results from the in vivo study show that the derivative of paracetamol 3 improves the functional repair of the sciatic nerve in rats, compared to paracetamol, and appears to be a promising agent for the treatment of peripheral nerve injuries in combination with its other actions.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Peperidou, Aikaterini
- Πεπερίδου, Αικατερίνη
Subjects
dc:subject × 14- Υβρίδια κινναμωμικού οξέος
- Κουμαρινικά παράγωγα
- Αναστολείς λιποξυγονάσης
- Αναστολείς θρυψίνης
- Αναστολείς καρβονικής ανυδράσης
- Hybrids of cinnamic acid
- Coumarin derivatives
- Inhibitors of lipoxygenase
- Inhibitors of trypsin
- Inhibitors of carvonic anhydrase
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες Υγείας
- Medical and Health Sciences
- Health Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/45848